A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

NCT02671942 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Roflumilast
DRUG: Placebo

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.